Last updated on April 2019

Effect of Mepolizumab in Severe Bilateral Nasal Polyps


Brief description of study

Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. This disease is characterized by the presence of polyps in the upper nasal cavity, originating from within the ostiomeatal complex. The presence of polyps can cause long-term symptoms such as prominent nasal obstruction, post-nasal drip, loss of smell, and discharge.

Mepolizumab (SB240563) is an Immunoglobulin G 1 [IgG1], kappa humanized monoclonal antibody (mAB) that blocks human interleukin-5 (hIL-5) from binding to the interleukin-5 (IL-5) receptor complex expressed on the eosinophil cell surface and thus inhibits signaling. Neutralization of IL-5 with mepolizumab has been shown to reduce blood, sputum and tissue eosinophils and hence is assumed to be a treatment option in a number of eosinophilic diseases including NP.

The aim of this randomized, double-blind, parallel group, phase 3 (PhIII) study is to assess the clinical efficacy and safety of 100 milligram (mg) subcutaneous (SC) mepolizumab as an add on to maintenance treatment in adults with severe bilateral NP. The study will include a 4-week run in period followed by randomization to a 52-week treatment period. Participants will receive mepolizumab 100 mg or placebo SC by the investigator or delegate via a pre-filled safety syringe every 4 weeks for 52 weeks. Throughout the entire study period (run in + treatment period + follow up), participants will receive a standard of care (SoC) for NP which consists of daily mometasone furorate (MF) nasal spray, and if required, saline nasal douching, occasional short courses of high dose oral corticosteroids (OCS) and/or antibiotics. The treatment period will consist of thirteen, 4-weekly doses of mepolizumab or placebo. In addition, up to the first 200 randomized participants will be followed up every other month for up to a further 6 months after the Visit 15 (7 months post last dose) in order to assess maintenance of response and to validate a physiological model derived from the previous Phase 2 study. Approximately 400 participants will be randomized (200 participants per treatment arm) in to the study. Total duration of the study will be 76 weeks for first 200 randomized participants and 52 weeks for remainder of participants who are not participating in the 6 months no treatment follow up.

Clinical Study Identifier: NCT03085797

Contact Investigators or Research Sites near you

Start Over

GSK Investigational Site

Baltimore, MD United States

GSK Investigational Site

Matthews, NC United States

GSK Investigational Site

Raleigh, NC United States

GSK Investigational Site

Winston-Salem, NC United States

GSK Investigational Site

Oklahoma City, OK United States

GSK Investigational Site

Medford, OR United States

GSK Investigational Site

Charleston, SC United States

GSK Investigational Site

Orangeburg, SC United States

GSK Investigational Site

San Antonio, TX United States

GSK Investigational Site

North Logan, UT United States

GSK Investigational Site

Darlinghurst, Australia

GSK Investigational Site

Westmead, Australia

GSK Investigational Site

Clayton, Australia

GSK Investigational Site

Melbourne, Australia

GSK Investigational Site

Murdoch, Australia

GSK Investigational Site

London, ON Canada

GSK Investigational Site

Ottawa, ON Canada

GSK Investigational Site

Montreal, QC Canada

GSK Investigational Site

Muenchen, Germany

GSK Investigational Site

Wiesbaden, Germany

GSK Investigational Site

Dresden, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Incheon, Korea, Republic of

GSK Investigational Site

Seongnam-si, Gyeonggi-do, Korea, Republic of

GSK Investigational Site

Brasov, Romania

GSK Investigational Site

Moscow, Russian Federation

GSK Investigational Site

Saint-Petersburg, Russian Federation

GSK Investigational Site

St. Petersburg, Russian Federation

GSK Investigational Site

Yaroslavl, Russian Federation

GSK Investigational Site

Darlington, United Kingdom

GSK Investigational Site

Colorado Springs, CO United States

GSK Investigational Site

Salt Lake City, UT United States

GSK Investigational Site

Rosario, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Mendoza, Argentina

GSK Investigational Site

Duesseldorf, Germany

GSK Investigational Site

Muenster, Germany

GSK Investigational Site

Luebeck, Germany

GSK Investigational Site

Seoul, Korea, Republic of

GSK Investigational Site

Amsterdam, Netherlands

GSK Investigational Site

Bucuresti, Romania

GSK Investigational Site

Cluj Napoca, Romania

GSK Investigational Site

Targu Mures, Romania

GSK Investigational Site

Saint-Peterburgh, Russian Federation

GSK Investigational Site

Stockholm, Sweden

GSK Investigational Site

Liverpool, United Kingdom

GSK Investigational Site

Manchester, United Kingdom

GSK Investigational Site

Rotherham, United Kingdom

GSK Investigational Site

Des Moines, IA United States

GSK Investigational Site

West Des Moines, IA United States

GSK Investigational Site

New York, NY United States

GSK Investigational Site

Hershey, PA United States

GSK Investigational Site

Vancouver, BC Canada

GSK Investigational Site

Saskatoon, SK Canada

GSK Investigational Site

Helsingborg, Sweden

GSK Investigational Site

Birmingham, AL United States

GSK Investigational Site

Newcastle upon Tyne, United Kingdom

GSK Investigational Site

Chicago, IL United States

GSK Investigational Site

Hamilton, ON Canada

GSK Investigational Site

Bethlehem, PA United States

GSK Investigational Site

Lynchburg, VA United States

GSK Investigational Site

Tuebingen, Germany

GSK Investigational Site

Frisco, TX United States

GSK Investigational Site

Dallas, TX United States

GSK Investigational Site

La Plata, Argentina

GSK Investigational Site

Mar del Plata, Argentina

GSK Investigational Site

Louisville, KY United States

GSK Investigational Site

McKinney, TX United States

GSK Investigational Site

Florida, FL Argentina

GSK Investigational Site

Marrero, LA United States

GSK Investigational Site

Piscataway, NJ United States

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Argentina

GSK Investigational Site

Meridian, ID United States

GSK Investigational Site

Roseville, CA United States

GSK Investigational Site

Lake Mary, FL United States

GSK Investigational Site

Columbia, MO United States

GSK Investigational Site

Riverside, CA United States

GSK Investigational Site

Richmond, VA United States

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Argentina

GSK Investigational Site

San Miguel de Tucumán, Argentina

GSK Investigational Site

Québec, Canada

GSK Investigational Site

Göteborg, Sweden

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.